Clinical trial services and drug development company Ergomed has entered a co-development agreement with Asarina Pharma to conduct the Phase IIb clinical trial of Sepranolone (UC1010) to treat premenstrual dysphoric disorder (PMDD).

PMDD is characterised by cyclic symptoms such as depression, anxiety, irritability, mood lability and loss of emotional control consistently at the latter part of the menstrual cycle, affecting a woman's personal and professional life.

The disorder is experienced during the fertile period beginning from menstruation until menopause.

Under the agreement, Ergomed will conduct Asarina’s multicentre, multinational, randomised Phase IIb clinical trial next year and will jointly invest into the trial in return for an equity stake in Asarina.

"Asarina’s proprietary Sepranolone is an endogenous, small molecule acting as a GABA-A modulating steroid antagonist (GAMSA)."

Ergomed CEO Dr Miroslav Reljanovic said: “We are delighted to be the co-development partner for Asarina as it embarks upon its Phase IIb clinical trial programme for Sepranolone, which has the potential to be a first-in-class therapy for this serious disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

See Also:

“This further expands the number of pipeline opportunities where we share in the potential upside as a drug is successfully developed through leveraging our expertise and experience in providing clinical trial services to support such development.”

Asarina’s proprietary Sepranolone is an endogenous, small molecule acting as a GABA-A modulating steroid antagonist (GAMSA).

Sepranolone has demonstrated its safety, efficacy and pharmacokinetics profile in an exploratory, double-blind, randomised, placebo-controlled, clinical phase I/II study conducted by Asarina on 120 women with PMDD.